Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brian Yang

Managing Editor

Beijing, China

Brian is in charge of overall China coverage within the APAC pharma news team. A veteran journalist, he has written extensively on R&D, regulatory, market access and business issues. Brian has led a team of writers providing industry-leading coverage in the second-largest health care market.

Latest From Brian Yang

China’s Regulator Has New Head But Will He Advance Further Reforms?

A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.

China Leadership

Hua Medicine's Chen On Product Launch, Bayer Partnership And Reimbursement

Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.

China Metabolic Disorders

Pfizer Facing Whistleblower Lawsuit Over China FCPA Concerns

Pfizer is facing a US lawsuit alleging wrongful termination and retaliation against a whistleblower after the company’s former director of Global Compliance Analytics discovered what he viewed to be potential violations in China of the US Foreign Corrupt Practices Act.

China Legal Issues

Pharma Hopes Rise As US Commerce Secretary Visits China

US Secretary of Commerce Gina Raimondo has made the first official visit to China by a US commerce official in three years, paving the way to possible improvements in bilateral relations. Despite ongoing geopolitical tensions as a major concern for US firms in China, some are returning to growth in the country. 

China Commercial

Chinese-Language Podcast: Anti-Corruption Campaign, PD-1 Going Global

In this latest Chinese-language podcast: China's latest crackdown on health sector non-compliance will have long-lasting effects on the sector; Chinese PD-1 inhibitor developers heading to the US.

China Commercial

China’s New Pharma Corruption Push Set For At Least A Year

As Beijing gets tougher in an all-out campaign to root out corruption and non-compliance in the pharma sector, more physician conferences are jeopardized and an increasing number of hospital presidents are placed under investigation. Meanwhile, one industry association issues new guidance for members. 

China Commercial
See All